A New PointClear UX White Paper

PointClear presents six healthcare trends and each one can be dramatically, positively impacted by a solid investment in user experience. 

Click Here to read the full article                                                            

I recently joined the Strategic Advisory Board of an interesting organization called the Clinical Groupware Collaborative [CGC]. The CGC is a relatively new and rapidly growing industry organization uniting companies in Health Information Technology around common goals to support healthcare through communication and collaboration. It’s members share a desire to see growth in the acquisition and use of affordable, easy-to-use, and interoperable EHR technology, especially among the very large group of "non-consumers" who have found legacy EMRs cumbersome, expensive, and technically challenging to use.

Several key initiatives underway, monitored and supported by the CGC are Meaningful Use, NHIN Direct and Smartplatforms to name a few. PointClear is helping it’s EHR clients with their roadmap projects to comply with Meaningful Use, particularly as it relates to provider/patient communications and information. We are closely watching the NHIN and Smartplatform pilots.

If you haven’t heard of the CGC you might want to check it out. It’s board of directors and members are industry leaders and innovators in healthcare technology. The Strategic Advisory Board, also made up of the HCIT leaders, has recently been formed to help the CGC navigate a very dynamic and rapidly evolving HIT marketplace, obviously catalyzed as a result of the American Recovery & Reinvestment Act of 2009 and the Health Reform Bill of 2010.

Stay tuned. I plan on blogging on interesting developments as they occur.

David Karabinos
President and Chief Executive Officer

Dr. Stice is the co-founder and CEO of Aruna Biomedical. He is also a Professor at the University of Georgia and is the director of the University’s Bioscience Center. He is considered a pioneer in cloning and stem cell research

Steve’s resume is crowded with firsts: he was the first
      + to clone a rabbit;
      + to clone bovine embryos from embryonic stem cell lines;
      + to clone a transgenic calf;
      + to clone the first human embryonic stem cells derived from discarded embryos;
      + to clone the first calf from a dead cow;
      + to clone the first motor neurons derived from human embryonic stem cells; and
      + to create the first human embryonic stem cell product to be commercialized.

In this podcast, Steve talks to us about stem cell research and where it is going. We also learn about how his company has developed a toolkit which is designed to accelerate the pace of neurological research for scientists working on treatments for spinal cord injuries and neurological diseases such as Parkinson’s, Huntington’s, Alzheimer’s, and even depression.

Jim Hudson is the founder and president of the newly opened HudsonAlpha Institute for Biotechnology located in Huntsville, Alabama.

Jim founded a company in 1987 known as Research Genetics where he served as its CEO until 2000. The company merged that year with Invitrogen in a deal valued at $138 million. Prior to the merger, Research Genetics had become the world’s leader in genetic linkage products and was a critical partner in the Human Genome Project coordinated by the U.S. Department of Energy and the National Institutes of Health. Jim has advised and incubated multiple companies in industries ranging from internet services to genetics research. In his role as President of the biotech institute, he is focused on building groundbreaking research and companies that can apply it for the benefit of society.

Jim is very well known in the biotech community and is often quoted by national, state and local media. This podcast is your opportunity to hear Jim in his own words talk about his life’s work and his newest and greatest venture.

Dr. Byrne is the Chief Technology Officer and co-founder of OcuMedic which won $100,000 for first place in the Alabama Launchpad business plan competition ending May 2008.

Incubated at Auburn University, the company has developed ground-breaking technology that allows for medicines to be taken via a person’s eye contacts instead of old-fashion eye drops. The medicines typically help with eye comfort, allergies, infections and inflammation.

This is an exciting development that could revolutionize eye care for humans and animals in the not too distant future.